Zusammenfassung
Matrix Metalloproteinasen (MMPs) hydrolysieren nahezu alle Komponenten der extrazellulären
Matrix (ECM). Diese Proteinasen spielen eine zentrale Rolle in vielen biologischen
Prozessen wie der Embryogenese, dem „Tissue remodeling” , der Wundheilung und der Angiogenese. Bisher sind die Gene von 26 MMPs identifiziert.
Die meisten sind zinkbindende Endopeptidasen aus mehreren Domänen. Neue Erkenntnisse
über die dreidimensionale Struktur verbessern das Verständnis über die funktionellen
Eigenschaften der MMPs. Im gesunden Gewebe ist die proteolytische Aktivität der
MMPs zum Erhalt der Homöostase innerhalb der ECM unter anderem durch endogene
MMP-Inhibitoren (TIMPs) reguliert. Eine Störung dieser Balance ist mit schweren
Erkrankungen wie Fibrose, Arthritis und malignen Tumoren assoziiert. Zahlreiche
Studien der letzten Jahre haben die Bedeutung der MMPs für Tumorentstehung, -wachstum,
-migration, -Angiogenese sowie Invasion und Metastasierung belegt. Bestimmte MMPs
wie die Gelatinasen (MMP-2 und MMP-9) haben spezielle Mechanismen, die eine Expression
an der Tumorinvasionsfront ermöglichen. MMPs können nicht länger als reine
Destruktoren der ECM betrachtet werden, sondern sind Teil eines komplizierten
Kommunikationssystems, durch das Epithelzellen und Tumorzellen mit dem Stroma
interagieren.
Summary
Matrix metalloproteinases (MMPs) hydrolyze most components of the extracellular
matrix (ECM). These proteinases play a central role in many biological processes
such as normal tissue remodeling, embryogenesis, wound healing and angiogenesis.
Currently about 26 MMP genes have been identified, and most are multidomain zinc
endopeptidases. Knowledge of their tertiary structure is crucial for the understanding
of the functional properties of MMPs. In healthy tissue a strict regulation of
MMPs is critical in order to maintain proper ECM homeostasis. Among other levels
of regulation, MMPs are precisely regulated by their main endogenous protein inhibitors
(TIMPs). Disruption of this balance results in serious diseases such as fibrosis,
arthritis, and tumour growth. Several studies have documented the importance of
MMP-mediated ECM destruction for tumour initiation, growth, migration, angiogenesis,
invasion and metastasis. Certain MMPs such as gelatinases (MMP-2, MMP-9) have
special mechanisms to localize at leading edges in tumour tissue. MMPs can no
longer be thought of solely as ECM destructionists, but as part of an elegant
communication system through which epithelial and tumor cells interact with the
stroma.
Literatur
1
Ahonen M, Baker A, Kähäri V M.
Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinase-3
inhibits invasion and induces apoptosis in melanoma cells.
Cancer Res.
1998;
58
2310-2315
2
Baker A H, Edwards D R, Murphy G.
Metalloproteinase inhibitors: biological actions and therapeutic opportunities.
J Cell Science.
2002;
115
3719-3727
3
Bode W.
Structural basis of matrix metalloproteinase function.
Biochem Soc Symp.
2003;
70
1-14
4
Cha H, Kopetzki E, Huber R, Lanzendorfer M, Brandstetter H.
Structural basis of the adaptive molecular recognition by MMP9.
J Mol Biol.
2002;
320
1065-1079
5
Coussens L M, Fingleton B, Matrisian L M.
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Science.
2002;
295
2387-2392
6
Egeblad M, Werb Z.
New functions for the matrix metalloproteinases in cancer progression.
Cancer.
2002;
2
161-174
7
Murphy F R, Issa R, Zhou X. et al .
Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor
of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition:
implications for reversibility of liver fibrosis.
J Biol Chem.
2002;
277
11 069-11 076
8
Nabeshima K, Inoue T, Shimao Y, Sameshima T.
Matrix metalloproteinases in tumor invasion: role for cell migration.
Pathol Int.
2002;
524
255-264
9
Nagase H, Barret A, Woessner J F.
Nomenclature and glossary of the matrix metalloproteinases.
Matrix.
1992;
Suppl 1
421-424
10
Pei D, Weiss S J.
Furin dependent intracellular activation of the human stromelysin 3 zymogen.
Nature.
1995;
375
244-247
11
Ratzinger G, Stoitzner P, Ebner S. et al .
Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans
cells and dermal dendritic cells from human and murine skin.
J Immunol.
2002;
168
4361-4371
12
Roeb E, Behrmann I, Grötzinger J, Breuer B, Matern S.
An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist.
FASEB J.
2000;
14
1671-1673
13
Roeb E, Dietrich C D, Winograd R, Arndt M, Breuer B, Fass J, Schumpelick V, Matern S.
Activity and cellular origin of gelatinases in patients with colon and rectal
carcinoma differential activity of matrix metalloproteinase-9.
Cancer.
2001;
92
2680-2691
14
Roeb E, Matern S.
Matrixmetalloproteinasen als Promotoren der Tumorinvasion und Metastasierung.
Z Gastroenterol.
2001;
39
807-813
15
Van Wart H E, Birkedal-Hansen H.
The cystein switch: A principle of regulation of metalloproteinase activity
with potential applicability to the entire matrix metalloproteinase gene family.
Proc Natl Acad Sci USA.
1990;
87
5578-5582
16
Visse R, Nagase H.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure,
function, and biochemistry.
Circ Res.
2003;
92
827-839
17
Vu T H, Shipley J M, Bergers G. et al .
MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis
of hypertrophic chondrocytes.
Cell.
1998;
93
411-422
18
Westermarck J, Kähäri V M.
Regulation of matrix metalloproteinase expression in tumor invasion.
FASEB J.
1999;
13
781-792
19
Wilhelm S M, Collier I E, Marmer B L. et al .
SV40-transformed human lung fibroblasts secrete a 92 kDa type IV collagenase
which is identical to that secreted by normal human macrophages.
J Biol Chem.
1989;
264
17 213-17 221
20 Woessner J F. The matrix metalloproteinase family. San Diego Academic Press
In Parks WC, Mecham RP (Hrsg). Matrix Metalloproteinases 1998: 1-14
21 Yu A E, Murphy A N, Stetler-Stevenson W G. Gelatinase A: Structure, Activation,
Regulation, and Substrate Specifity. San Diego. Academic Press In Parks,
WC, Mecham RP (eds). Matrix Metalloproteinases 1998: 85-105
22
Marimastat: BB 2516, TA 2516.
Drugs RD.
2003;
4
198-203
Prof. Dr. med. Elke Roeb
Medizinische Klinik III, Universitätsklinikum der RWTH Aachen
Pauwelsstraße 30
52057 Aachen
Phone: 0241/8089200, -89198
Fax: 0241/8082455
Email: eroeb@ukaachen.de